Global Biopharmaceutical Company Bristol-Myers Squibb was quite enthusiastic when it took up a $2.5 billion project to develop a hepatitis C drug. However, it has been recently revealed that the company has announced the discontinuation of the development of the drug.

Eight people, who took part in the initial test of clinical trial, were admitted in a hospital and one of them even lost his life. The company officials were of the view that it has not been proved that the drug has caused death or is behind the hospitalization of other volunteers.

Then also, they have decided to suspend the testing of the drug. People safety is of paramount importance, and this is the reason that they discontinued their trials from August 1. “The decision to halt development of BMS-986094 has been guided by our overriding interest in protecting patients”, said Elliott Sigal, who is the Executive Vice President of Bristol-Myers Squibb.

Sigal said that they are not going to end this matter so soon. They have made a special investigation team, which will look into the safety issue of the trial. It is vital to know what caused the failure of initial clinical trial. Checkups will be done of patients, who have been admitted in hospital.